Late-breaking primary results from the DESTINYBreast-12 trial at ESMO24

ESMO posted on LinkedIn:

“At ESMO24, late-breaking primary results from the DESTINYBreast-12 trial revealed substantial and durable efficacy with the antibody–drug conjugate (ADC) trastuzumab deruxtecan in patients with HER2+ metastatic Breast Cancer, including those with brain metastases. Encouraging data were also presented from the smaller ICARUS-BREAST01 study with the novel anti-HER3 ADC patritumab deruxtecan in patients with HR+/HER2- Advanced Breast Cancer after failure of CDK-4/6 inhibitor therapy.

Read the full-data commentary by Philippe Aftimos on the ESMO Daily Reporter.”

Source: ESMO/LinkedIn